Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | DRD4 | P21917 | 1/20 | 0.42 |
| ▸ | DRD3 | P35462 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5601933 | 0.97 | DRD2 (0.41) | DRD2DRD4DRD3PKMGAA | |
| SCHEMBL5600054 | 0.97 | DRD2 (0.41) | DRD2DRD4DRD3PKMGAA | |
| SCHEMBL5601787 | 0.97 | DRD2 (0.41) | DRD2DRD4DRD3PKMGAA | |
| SCHEMBL1901033 | 0.97 | DRD2 (0.41) | DRD2DRD4DRD3PKMGAA | |
| SCHEMBL5601758 | 0.97 | DRD2 (0.41) | DRD2DRD4DRD3PKMGAA | |
| SCHEMBL5601528 | 0.97 | DRD2 (0.41) | DRD2DRD4DRD3PKMGAA | |
| SCHEMBL5599984 | 0.97 | DRD2 (0.41) | DRD2DRD4DRD3PKMGAA | |
| SCHEMBL5602242 | 0.97 | DRD2 (0.41) | DRD2DRD4DRD3PKMGAA | |
| Hydrochloric Acid SCHEMBL27290402 | 0.94 | DRD2 (0.39) | DRD2DRD4DRD3PKMGAA | |
| SCHEMBL5603702 | 0.94 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 265 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111655695-B | Substituted furopyrimidine compounds as PDE1 inhibitors | 达特神经科学有限公司 | 2025-05-27 | — | — | CN | claimed |
| CN-118782152-B | Organic heterocyclic biomarker for wild and cultivated four-large family fish population and application thereof | 中国水产科学研究院长江水产研究所 | 2025-05-20 | — | — | CN | claimed |
| CN-118791418-A | Indole compound and preparation method and application thereof | 纽欧申医药(上海)有限公司 | 2024-10-18 | — | — | CN | claimed |
| WO-2024213032-A1 | INDOLE COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF | 纽欧申医药(上海)有限公司 | 2024-10-17 | — | — | WO | claimed |
| CN-118782152-A | Organic heterocyclic biomarker for wild and cultivated four-large family fish population and application thereof | 中国水产科学研究院长江水产研究所 | 2024-10-15 | — | — | CN | claimed |
| WO-2024125600-A1 | HETEROCYCLIC COMPOUNDS ACTING AS KRAS INHIBITORS, PREPARATION THEREFOR AND THERAPEUTIC USE THEREOF | 上海科州药物研发有限公司 | 2024-06-20 | — | — | WO | claimed |
| CN-117813306-A | Heterocyclic compounds as KRAS inhibitors, their preparation and therapeutic use | 上海科州药物研发有限公司 | 2024-04-02 | — | — | CN | claimed |
| CN-117586180-A | Compounds useful as inhibitors of voltage-gated sodium channels | 广州费米子科技有限责任公司 | 2024-02-23 | — | — | CN | claimed |
| WO-2024037616-A1 | COMPOUND CONTAINING CYCLOHEXYL | 正大天晴药业集团股份有限公司 | 2024-02-22 | — | — | WO | claimed |
| CN-116332910-A | 2-aminopyrimidine derivatives as kinase inhibitors, preparation and use thereof | 江苏威凯尔医药科技有限公司 | 2023-06-27 | — | — | CN | claimed |
| EP-1720544-B1 | NOVEL AZABICYCLIC DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | SERVIER LAB (FR) | 2008-03-19 | — | — | EP | claimed |
| US-20080021031-A1 | SELENOPHENE COMPOUNDS | NATIONAL HEALTH RESEARCH INSTITUTE (TW) | 2008-01-24 | — | — | US | claimed |
| US-7276567-B2 | Heterocyclic substituted metallocene compounds for olefin polymerization | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2007-10-02 | — | — | US | claimed |
| US-20070197625-A1 | Azabicyclic compounds, a process for their preparation and pharmaceutical compositions containing them. | LES LABORATORATIES SERVIER (FR) | 2007-08-23 | — | — | US | claimed |
| WO-2007070046-A1 | HALOGEN SUBSTITUTED HETEROATOM-CONTAINING METALLOCENE COMPOUNDS FOR OLEFIN POLYMERIZATION | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2007-06-21 | — | — | WO | claimed |
| US-20070135623-A1 | Halogen substituted heteroatom-containing metallocene compounds for olefin polymerization | EXXONMOBIL CHEMICAL PATENTS INC. | 2007-06-14 | — | — | US | claimed |
| US-5231083-A | Cardiovascular disorders and anticoagulants | HOECHST AKTIENGESELLSCHAFT (DE) | 1993-07-27 | — | — | US | claimed |
| US-5043346-A | Amino acid esters, pharmaceuticals containing them, and the use thereof in learning disorders | HOECHST AKTIENGESELLSCHAFT (DE) | 1991-08-27 | — | — | US | claimed |
| US-4713459-A | TRANSFERRING OXYGEN FOR HEMORRHAGE VICTIMS, PRESERVING ORGANS FOR SURGERY | THE GREEN CROSS CORPORATION (JP) | 1987-12-15 | — | — | US | claimed |
| US-4558038-A | HYPOTENSIVE AGENTS | USV PHARMACEUTICAL CORP. (US) | 1985-12-10 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135623-A1 | Halogen substituted heteroatom-containing metallocene compounds for olefin polymerization | OPRM1, POLM, AP1M1 | DRD2 1099/4885DRD4 697/4885DRD3 969/4885 |
| US-20080021031-A1 | SELENOPHENE COMPOUNDS | CNR2, CNR1, SELENOI | DRD2 176/4885DRD4 160/4885DRD3 336/4885 |
| US-20070197625-A1 | Azabicyclic compounds, a process for their preparation and pharmaceutical compositions containing them. | HRH2, HNMT, HRH1 | DRD2 877/4885DRD4 1781/4885DRD3 1934/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.